Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558982 · ClinicalTrials.gov registry record · Phase 2
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Georgetown University.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT05558982: Active Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Georgetown University.
NCT05558982 is a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Georgetown University. The registered enrollment target is 22 participants, below the 183-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05558982, a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Georgetown University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG BXCL701
Study Locations (3)
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
- Medstar Washington Hospital Center - Washington D.C.
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What the registry record for NCT05558982 still lists
NCT05558982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 183-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05558982 reports a single indexed study location in District of Columbia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05558982 about?
NCT05558982 is a clinical study titled "BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
What is the current status of trial NCT05558982?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2023-08-16. Estimated completion is 2027-11.
What conditions does trial NCT05558982 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05558982?
The interventions under investigation include: Pembrolizumab (DRUG), BXCL701 (DRUG).
Who is sponsoring clinical trial NCT05558982?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05558982 being conducted?
This trial has 3 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05558982's enrollment target sits among peer trials
22 17th of 20 higher than 3 of 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI